Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

MeCP2-E1 isoform is a dynamically expressed, weakly DNA-bound protein with different protein and DNA interactions compared to MeCP2-E2.

Martínez de Paz A, Khajavi L, Martin H, Claveria-Gimeno R, Tom Dieck S, Cheema MS, Sanchez-Mut JV, Moksa MM, Carles A, Brodie NI, Sheikh TI, Freeman ME, Petrotchenko EV, Borchers CH, Schuman EM, Zytnicki M, Velazquez-Campoy A, Abian O, Hirst M, Esteller M, Vincent JB, Malnou CE, Ausió J.

Epigenetics Chromatin. 2019 Oct 10;12(1):63. doi: 10.1186/s13072-019-0298-1.

2.

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Piqué L, Martinez de Paz A, Piñeyro D, Martínez-Cardús A, Castro de Moura M, Llinàs-Arias P, Setien F, Gomez-Miragaya J, Gonzalez-Suarez E, Sigurdsson S, Jonasson JG, Villanueva A, Vidal A, Davalos V, Esteller M.

Oncogene. 2019 Nov;38(45):7106-7112. doi: 10.1038/s41388-019-0936-x. Epub 2019 Aug 13.

PMID:
31409895
3.

Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.

Good KV, Martínez de Paz A, Tyagi M, Cheema MS, Thambirajah AA, Gretzinger TL, Stefanelli G, Chow RL, Krupke O, Hendzel M, Missiaen K, Underhill A, Landsberger N, Ausió J.

Epigenetics. 2017;12(11):934-944. doi: 10.1080/15592294.2017.1380760. Epub 2017 Dec 5.

4.

MeCP2, A Modulator of Neuronal Chromatin Organization Involved in Rett Syndrome.

Martínez de Paz A, Ausió J.

Adv Exp Med Biol. 2017;978:3-21. doi: 10.1007/978-3-319-53889-1_1. Review.

PMID:
28523538
5.

HMGNs: The enhancer charmers.

Martínez de Paz A, Ausió J.

Bioessays. 2016 Mar;38(3):226-31. doi: 10.1002/bies.201500157. Epub 2015 Dec 28. Review.

PMID:
26709929
6.

Circadian cycle-dependent MeCP2 and brain chromatin changes.

Martínez de Paz A, Sanchez-Mut JV, Samitier-Martí M, Petazzi P, Sáez M, Szczesna K, Huertas D, Esteller M, Ausió J.

PLoS One. 2015 Apr 13;10(4):e0123693. doi: 10.1371/journal.pone.0123693. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136470.

7.

MeCP2: the long trip from a chromatin protein to neurological disorders.

Ausió J, Martínez de Paz A, Esteller M.

Trends Mol Med. 2014 Sep;20(9):487-98. doi: 10.1016/j.molmed.2014.03.004. Epub 2014 Apr 21. Review.

PMID:
24766768
8.

An increase in MECP2 dosage impairs neural tube formation.

Petazzi P, Akizu N, García A, Estarás C, Martínez de Paz A, Rodríguez-Paredes M, Martínez-Balbás MA, Huertas D, Esteller M.

Neurobiol Dis. 2014 Jul;67:49-56. doi: 10.1016/j.nbd.2014.03.009. Epub 2014 Mar 19.

9.

Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.

Rodriguez-Paredes M, Martinez de Paz A, Simó-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, Vázquez-Cedeira M, Lazo PA, Carneiro F, Moura CS, Vieira J, Teixeira MR, Esteller M.

Oncogene. 2014 May 22;33(21):2807-13. doi: 10.1038/onc.2013.239. Epub 2013 Jun 17.

10.

Impaired in vivo binding of MeCP2 to chromatin in the absence of its DNA methyl-binding domain.

Stuss DP, Cheema M, Ng MK, Martinez de Paz A, Williamson B, Missiaen K, Cosman JD, McPhee D, Esteller M, Hendzel M, Delaney K, Ausió J.

Nucleic Acids Res. 2013 May;41(9):4888-900. doi: 10.1093/nar/gkt213. Epub 2013 Apr 4.

11.

Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells.

Celià-Terrassa T, Meca-Cortés O, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, Álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM.

J Clin Invest. 2012 May;122(5):1849-68. doi: 10.1172/JCI59218. Epub 2012 Apr 16.

Supplemental Content

Loading ...
Support Center